Affiliation:
1. School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
2. Division of Cardiac Surgery
3. Division of Cardiology, St. Michael's Hospital, Toronto, Canada
Abstract
Purpose of review
Chronic primary mitral regurgitation (MR) is a common heart valve disease with a rising prevalence with the aging populations worldwide. The timing of surgical intervention in patients who have severe MR but remain asymptomatic is often debated. Herein we synthesize the latest American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/ European Association for Cardio-Thoracic Surgery (ESC/EACTS) heart valve guidelines in such patients and illustrate how circulating and/or imaging biomarkers can be used to help refine decision making algorithms.
Recent findings
The approach to decision making and strength of guideline recommendations in patients with asymptomatic stage C1 (left ventricular ejection fraction [LVEF] > 60% and left ventricular end systolic dimension [LVESD] < 40 mm) and stage C2 disease (LVEF ≤ 60% and/or LVESD ≥ 40 mm) are reviewed. While surgical intervention is clearly indicated in patients with stage C2 disease, a multifaceted approach that integrates repairability, expertise, sub-clinical evidence of left ventricular (LV) dysfunction, and patient preferences is required to identify the optimal approach to surveillance vs. surgery. The role of imaging (3D echocardiography, contrast echocardiography, left ventricular global longitudinal strain, and cardiovascular magnetic resonance imaging [CMR]) and circulating (natriuretic peptides) biomarkers in decision making is also reviewed.
Summary
The decision making around timing of intervention in chronic primary MR requires a personalized approach that is based on accurate assessments of severity of MR, LV dimensions, LV function, valve morphology/repairability, surgeon and center expertise, and patient wishes. Biomarkers hold promise in refining decision making.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference52 articles.
1. Mitral valve disease—morphology and mechanisms;Levine;Nat Rev Cardiol,2015
2. Outcome and undertreatment of mitral regurgitation: a community cohort study;Dziadzko;Lancet,2018
3. Mitral regurgitation;Enriquez-Sarano;Lancet,2009
4. Mitral-valve repair for mitral-valve prolapse;Verma;N Engl J Med,2009
5. Mitral valve incompetence: epidemiology and causes;Ancona;E-J Cardiol Pract,2018